Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches
出版年份 2019 全文链接
标题
Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches
作者
关键词
-
出版物
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 25, Issue 29, Pages 3920-3928
出版商
Baishideng Publishing Group Inc.
发表日期
2019-08-06
DOI
10.3748/wjg.v25.i29.3920
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.
- (2019) Teresa Troiani et al. JOURNAL OF CLINICAL ONCOLOGY
- CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
- (2019) Eric Xueyu Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I/II study of pexa-vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer: Safety report.
- (2019) Maria Pia Morelli et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA-004Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer
- (2018) J Bendell et al. ANNALS OF ONCOLOGY
- Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer
- (2018) Takeshi Ishikawa et al. INTERNATIONAL JOURNAL OF CANCER
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
- (2018) Felix S. Lichtenegger et al. Frontiers in Immunology
- PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
- (2018) Magalie Dosset et al. OncoImmunology
- Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).
- (2018) Alexander Stein et al. JOURNAL OF CLINICAL ONCOLOGY
- LBA37_PRNeoadjuvant ipilimumab plus nivolumab in early stage colon cancer
- (2018) M Chalabi et al. ANNALS OF ONCOLOGY
- LBA19Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy
- (2018) A Grothey et al. ANNALS OF ONCOLOGY
- LBA18_PRDurable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)
- (2018) H-J J Lenz et al. ANNALS OF ONCOLOGY
- Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
- (2018) Christopher S. Garris et al. IMMUNITY
- Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).
- (2017) Howard S. Hochster et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring aPOLEMutation
- (2017) Jun Gong et al. Journal of the National Comprehensive Cancer Network
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Oncolytic Viruses in Cancer Treatment
- (2017) Sean E. Lawler et al. JAMA Oncology
- Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma
- (2016) J. Chesney et al. ANNALS OF ONCOLOGY
- The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment
- (2016) LUBOS HOLUBEC et al. ANTICANCER RESEARCH
- Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
- (2016) Etienne Becht et al. CLINICAL CANCER RESEARCH
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer.
- (2016) Austin G. Duffy et al. JOURNAL OF CLINICAL ONCOLOGY
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
- (2016) Marios Giannakis et al. Cell Reports
- Chimeric antigen receptor T-cell therapy for solid tumors
- (2016) Kheng Newick et al. Molecular Therapy-Oncolytics
- Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer
- (2015) Yun-Huan Zhen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant
- (2015) Kobe Reynders et al. CANCER TREATMENT REVIEWS
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
- (2015) S. C. Katz et al. CLINICAL CANCER RESEARCH
- Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors
- (2015) Hinrich Abken Immunotherapy
- Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).
- (2015) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer
- (2015) Se Hoon Park et al. MOLECULAR THERAPY
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenicity of somatic mutations in human gastrointestinal cancers
- (2015) E. Tran et al. SCIENCE
- Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
- (2015) Patrick A. Ott et al. Frontiers in Oncology
- Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial
- (2014) Hans-Joachim Schmoll et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
- (2013) Paul F Robbins et al. NATURE MEDICINE
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of Adaptive Immunity by the Innate Immune System
- (2010) A. Iwasaki et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now